Company receiving an approval from Board of Directors and/or Annual General Meeting about the signing of Share Purchase Agreement and other related contract. Canceled due to changes in method of payment. As
quarter 1/2020 Baht 44.91 million was decreased of Baht 12.19 million or 21.35% from the revenues of Baht 57.10 million of the quarter 1/2019. The revenue was decreased from the contract manufacturing and
: 50,000,000 Baht Interest Rate : 7 % per year 2 Term of Loan : 2 year Payment of Interest : Every Month Payment of Principal : Due date of payment on contract Collateral : None 4) Objective Working Capital for
: Every Month Payment of Principal : Due date of payment on contract Collateral : None 4) Objective Working Capital for development of projects. 1.2 The Loan amount of 100,000,000 baht for 2 year (Due date
Company has assessed the impact from such delay in project completion. In relation to this project, there were unbilled contract revenue amounting to Baht 57 million, which the collectability are directly
of lease contract between IMP and the Office of the Privy Purse, Bureau of the Royal Household and/or Bejaratana-Suvadhana Foundation both in terms of expenses and building usage. Other risks
Laboratory and Research Center (“AMARC”). Costs and Expenses The Company reported the consolidated costs and expenses for Q1/2019 of Baht 345.54 million, nearby of Q1/2018 of Baht 345.61 million decreased by
booked in year 2018 for chronic diseases were then subtracted accordingly. However, the service revenues (mainly received from Asia Medical and Agricultural Laboratory and Research Center Co., Ltd “AMARC
to the hospital. In regard to the subsidiary, Asia Medical & Agricultural Laboratory and Research Center (“AMARC”), its service revenues grew by 12.60% as it provides laboratory testing and analyzing